Premium
Fascin‐1 expression in canine cutaneous and oral melanocytic tumours
Author(s) -
Yamada N.,
Mori T.,
Murakami M.,
Noguchi S.,
Sakai H.,
Akao Y.,
Maruo K.
Publication year - 2012
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2011.00300.x
Subject(s) - fascin , melanoma , immunohistochemistry , malignancy , staining , medicine , pathology , stage (stratigraphy) , oncology , cancer research , biology , paleontology
Fascin‐1 expression was examined in 9 cutaneous melanocytomas and 47 oral melanomas. The cases were scored on the basis of extent and intensity of staining, and combined scores were calculated. Fascin‐1 expression was observed in 5/9 (56%) melanocytomas and 46/47 (98%) melanomas. The combined score for fascin‐1 was significantly greater in stage III/IV melanomas than in stage I/II melanomas ( P < 0.05). In addition, strong fascin‐1 staining was associated with a significantly shortened survival time ( P < 0.05). The results of this study suggest that fascin‐1 overexpression correlates with the malignancy of canine melanoma and has the potential to be a new immunohistochemical marker to predict the clinical course of canine melanoma. In addition, targeted therapy for fascin‐1 may represent a new strategy for the treatment of canine melanoma.